{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-055055","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.043117+00:00","generated_at":"2026-06-26T01:35:05.019400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiniksa Q1 2022 ARCALYST net revenue $22.2M; net loss narrows to $25.2M; FY2022 guidance $115-130M","bullets":["ARCALYST net revenue $22.2M in Q1 2022 versus $0 in Q1 2021; total revenue $32.2M including $10M collaboration revenue.","Net loss $25.2M, improved from $49.5M loss in Q1 2021; cash $145.6M, no debt.","Full-year 2022 ARCALYST net revenue guidance $115M-$130M; cash expected to fund operations into at least 2024.","Strategic collaboration with Huadong Medicine for Asia Pacific rights: $22M upfront, up to $640M milestones, tiered royalties.","Over 400 prescribers for ARCALYST since launch; ~95% coverage approval; ~60% patients retained on therapy through Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-055055","json":"https://secwatch.observer/filing/0001104659-22-055055.json","markdown":"https://secwatch.observer/filing/0001104659-22-055055.md","text":"https://secwatch.observer/filing/0001104659-22-055055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922055055/0001104659-22-055055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922055055/tm2214107d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:35:05.019400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}